clofarabine has been researched along with fludarabine in 34 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (fludarabine) | Trials (fludarabine) | Recent Studies (post-2010) (fludarabine) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 3,452 | 812 | 1,415 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 23 (67.65) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Clayton, SD; Montgomery, JA; Riordan, JM; Secrist, JA; Shortnacy-Fowler, AT | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S | 1 |
| Adachi, S; Carrera, CJ; Carson, DA; Chao, Q; Cottam, HB; Genini, D; Leoni, LM; Rose, DW | 1 |
| Keating, MJ; Nowak, BJ; Plunkett, W; Yamauchi, T | 1 |
| Albertioni, F; Elford, H; Eriksson, S; Flordal, E; Lagercrantz, S; Liliemark, J; Månsson, E; Spasokoukotskaja, T | 1 |
| Cass, CE; Damaraju, VL; King, KM; Lang, T; Mowles, DA; Ng, AM; Tackaberry, TE; Vickers, MF; Yao, SY; Young, JD | 1 |
| Andersson, BS; Valdez, BC | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC | 1 |
| Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL | 1 |
| Jacobson, PA; Jensen, K; Johnson, LA; Kachler, S; Kirstein, MN; Klotz, KN; Lamba, J | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B | 1 |
| Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC | 1 |
| Aweeka, F; Dvorak, CC; Huang, L; Lizak, P; Long-Boyle, J | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E | 1 |
| Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY | 1 |
| Boelens, JJ; Egas, AC; Langenhorst, JB; Punt, AM; van Kesteren, C; van Maarseveen, EM | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Appelhans, D; Danani, A; Deriu, MA; Gorzkiewicz, M; Grasso, G; Janaszewska, A; Klajnert-Maculewicz, B; Pułaski, Ł; Studzian, M | 1 |
| Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB | 1 |
| Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC | 1 |
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Green, S; Schultz, L | 1 |
| Carlow, DC; Schofield, RC; Scordo, M; Shah, G | 1 |
2 review(s) available for clofarabine and fludarabine
| Article | Year |
|---|---|
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine | 2010 |
Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Topics: Bendamustine Hydrochloride; Burkitt Lymphoma; Child; Clofarabine; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Young Adult | 2023 |
6 trial(s) available for clofarabine and fludarabine
| Article | Year |
|---|---|
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
26 other study(ies) available for clofarabine and fludarabine
| Article | Year |
|---|---|
Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
Topics: Animals; Antimetabolites, Antineoplastic; Escherichia coli; HIV; Humans; Leukemia P388; Mice; Purine-Nucleoside Phosphorylase; Structure-Activity Relationship; Tumor Cells, Cultured; Vidarabine | 1992 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine | 1999 |
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arabinonucleosides; B-Lymphocytes; Cell Survival; Cladribine; Clofarabine; Comet Assay; Deoxyadenosines; DNA Damage; DNA, Mitochondrial; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Potentials; Microinjections; Mitochondria; Time Factors; Tumor Cells, Cultured; Vidarabine | 2000 |
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Arabinonucleotides; Clofarabine; Cyclophosphamide; DNA; DNA Repair; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleosides; Time Factors; Vidarabine | 2001 |
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cell Line; Cladribine; Clofarabine; Cytogenetics; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia; Phenotype; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 2003 |
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Biological Transport; Cell Line; Cladribine; Clofarabine; Humans; Membrane Transport Proteins; Recombinant Proteins; Vidarabine; Xenopus laevis | 2006 |
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2011 |
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Binding, Competitive; CHO Cells; Cladribine; Clofarabine; Cricetinae; Cricetulus; Cytotoxins; Humans; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Vidarabine | 2012 |
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2014 |
Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
Topics: Adenine Nucleotides; Arabinonucleosides; Chromatography, Liquid; Clofarabine; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Chromatin Assembly and Disassembly; Clofarabine; Depsipeptides; DNA Damage; Drug Synergism; Histone Code; Humans; Metabolic Networks and Pathways; Tumor Cells, Cultured; Vidarabine | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine | 2017 |
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2017 |
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Chromatography, Liquid; Clofarabine; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Isotopes; Limit of Detection; Tandem Mass Spectrometry; Transplantation Conditioning; Vidarabine | 2017 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine | 2018 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clofarabine; Dendrimers; Humans; Maltose; Polypropylenes; Surface Plasmon Resonance; U937 Cells; Vidarabine | 2019 |
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2022 |
Quantification of Clofarabine and Fludarabine in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chromatography, High Pressure Liquid; Clofarabine; Humans; Tandem Mass Spectrometry; Vidarabine | 2024 |